PT - JOURNAL ARTICLE AU - Altabás-González, Irene AU - Pego-Reigosa, José María AU - Mouriño-Rodriguez, Coral AU - Jiménez-Otero, Norman AU - Hernández-Martín, Andrea AU - Font-Urgelles, Judit AU - Casafont-Sole, Ivette AU - Roman-Ivorra, José Andrés AU - Rubia-Navarro, Marta De La AU - Galindo-Izquierdo, María AU - Salman-Montes, Tarek AU - Narváez, Javier AU - Vidal-Montal, Paola AU - García-Villanueva, María Jesús AU - Garrote-Corral, Sandra AU - Blázquez-Cañamero, María Ángeles AU - Marras-Fernández, Carlos AU - Piqueras-García, María AU - Martínez-Barrio, Julia AU - Sánchez-Lucas, Marina AU - Cortés-Hernández, Josefina AU - Penzo, Eleonora AU - Calvo-Alen, Jaime AU - Jiménez De Aberásturi, Juan Ramón De Dios AU - Álvarez-Rodríguez, Belén AU - Vasques-Rocha, Margarida AU - Tomero, Eva AU - Menor-Almagro, Raúl AU - Gandía-Martínez, Myriam AU - Gómez-Puerta, José A AU - Ramos-Giráldez, Consuelo AU - Trapero-Pérez, Carmen AU - Díez-Álvarez, Elvira AU - Moriano, Clara AU - Muñoz-Jiménez, Alejandro AU - Rúa-Figueroa, Íñigo TI - LP-191 Baseline profile of systemic lupus erythematosus patients on treatment with belimumab of a Spanish multicenter cohort AID - 10.1136/lupus-2023-KCR.266 DP - 2023 Jul 01 TA - Lupus Science & Medicine PG - A161--A161 VI - 10 IP - Suppl 1 4099 - http://lupus.bmj.com/content/10/Suppl_1/A161.1.short 4100 - http://lupus.bmj.com/content/10/Suppl_1/A161.1.full SO - Lupus Sci Med2023 Jul 01; 10 AB - Background Baseline profile of systemic lupus erythematosus patients on treatment with Belimumab of a Spanish multicenter cohort.Methods Multicenter retrospective and longitudinal cohort study. Data was collected at baseline, 6, 12 months and in the last visit available. Different periods (2010–2015/2016–2021) were compared.Results 324 patients (91% female) were enrolled. Mean (±SD) age at diagnosis: 31.8 years (±11.9); mean disease duration of 8.7 years (±9.07). At baseline, mean SLEDAI-2K score was 10.4 (±5.25); 152 (47.5%) patients had damage with a mean SDI score of 0.83 (±1.2). 289 patients (89.2%) had received DMARDs before BLM: cDMARDS in 282 (87%) and bDMARDs in 74 patients (22.8%); 164 (51.9%) had received more than one cDMARDs, methotrexate being the most frequently used (44.4%) and Rituximab the most frequent bDMARDs used (80%). Antimalarials were used in 83,2% and glucocorticoids (GC) in 91.2%, with a mean dose of 12.3 mg/day. 67.9% of patients were receiving more than 5 mg/day and 58.4% more than 7.5 mg/day of prednisone. BLM was used in monotherapy in 30.5% of subjects. Reasons of prescription: disease activity in 95% of patients and/or as a GC sparing agent in 59%. Only a few patients received BLM just for maintenance (4/322) or save GC (8/322). At baseline, 6 patients (1.9%) were in DORIS-21-remission and LLDAS. The main reasons of prescription for ongoing activity were arthritis (65.4%), cutaneous (40.7%) or both (81%). No differences were observed in prescription reasons between periods.Conclusions Belimumab was mainly prescribed after the use of other DMARDs and more than 50% had received at least 2 DMARDs and were receiving GC at medium doses. Most patients received BLM due to active disease and/or as GC sparing agent. Activity in articular and cutaneous domains were the main reasons of indication. No changes in prescription habits were identified.